Breast cancer patients may not hear all their options

Cancer care teams should make efforts to work more collaboratively

 

Following a positive lab test for breast cancer, many women may not be informed of all their treatment options, according to a new study published...  http://ow.ly/auyqr

Why SYMPHONY with MammaPrint...

Physical Activity in Cancer Survivors Associated With Better Health Outcomes

Physical Activity in Cancer Survivors Associated With Better Health...

A new study from the National Cancer Institute shows that physical activity is associated with lower mortality rates in patients with breast and...http://ow.ly/aO45R

Great article..."Does diet really matter in breast cancer?"

Does diet really make a difference when it comes to breast cancer?

ow.ly

Every weekday, a CNNHealth expert doctor answers a viewer question. On Friday, it's Dr. Melina Jampolis, a physician nutrition specialist. Asked by... http://ow.ly/aPz4B

The benefit —100% definitive results

SYMPHONY results are valid at the time of diagnosis. Agendia’s signatures were developed independent of drug therapy. Thus, the actual test result will indicate the prognosis for your patient if no therapy is provided. You do not have to assume that your patient will remain on a course of therapy to validate the test results. Which makes the SYMPHONY suite of genomic assays the perfect accompaniment to your current protocols.

The Symphony^TM Personalized Breast Cancer Profile: Agendia offers a variety of breast cancer assays to help personalize the patient's treatment by looking at what their likelihood of recurrence truely is.

• MammaPrint^®: The only FDA-cleared Breast Cancer Recurrence Test
• TargetPrint^®: Analysis for ER, PR & HER2 Status
• BluePrint™: Molecular Subtyping Profile for Breast Cancer Patients
• TheraPrint^®: 56 Therapy Gene Assay

Agendia Inc: When biology speaks, we listen!

Agendia Inc: When biology speaks, we listen!: Agendia is part of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patien...

Achieving definitive results by analyzing the entire human genome.

The SYMPHONY™ signature development process began by identifying two groups of women: those who had a recurrence within five years following surgery and those who were cancer free at five years. The entire human genome of 25,000 genes was analyzed for both groups, and the resulting differences in gene expression were captured. What’s more significant, is that none of the women in either group were treated with either chemo or hormonal therapy. This control process allowed the pure biology of the tumors to be followed for more than 20 years — ultimately ensuring a definitive, actionable result for each of your patients.